Analysis of KIT gene mutations in patients with melanoma of the head and neck mucosa: A retrospective clinical report

Imagem de Miniatura
Arquivos
art_MENDONçA_Analysis_of_KIT_gene_mutations_in_patients_with_2018.PDF (1.26 MB)
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
IMPACT JOURNALS LLC
Autores
MENDONçA, U. B. T. de
LIMA, R. R. M. A.
Citação
ONCOTARGET, v.9, n.33, p.22886-22894, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Unlike their cutaneous counterparts, head and neck mucosal malignant melanomas (HNMM) are more aggressive, and their prognostic markers have not been fully elucidated. This study, comprising 28 patients with HNMM, aimed to establish the relationship between different mutations and outcome, define the incidence of KIT mutations in HNMM, and identify the correlation among therapeutic options, histopathological findings, demographic data, and clinical response. Clinical analysis included patient characteristics, staging, primary and palliative treatments, and disease-free survival and overall survival (OS). Progression-free survival and OS were analyzed. Paraffin blocks were selected following histologic analyses, enabling DNA extraction. PCR amplification of exons 9, 11, 13, and 17, with different DNA concentrations, was performed. Patients were predominantly females (57%) and aged 27-85 years. All patients underwent surgery; 17 received adjuvant radiotherapy, and recurrences occurred in 82% patients. Oncologic mutations in KIT were found in 7 of 7 tumors, 3 in exon 9, 3 in exon 11, and 1 in exon 13. Predictive factors for recurrence were mitotic rate, vascular invasion, and perineural spread. There were no significant differences in DFS and OS according to KIT mutation. Our study results suggest that some patients might benefit from appropriate targeted therapy with kinase inhibitors. ©Mendonça et al.
Palavras-chave
c-kit, KIT, Mucosal melanoma, Mutation, Proto-oncogene
URI
https://observatorio.fm.usp.br/handle/OPI/31025
Referências
  1. Winnenpenninckx, V., Lazar, V., Michiels, S., Dessen, P., Stas, M., Alonso, S.R., Avril, M., Sarasin, A., Gene expression profiling of primary cutaneous melanoma and clinical outcome (2006) J Natl Cancer Inst., 98, pp. 472-482. , https://doi.org/10.1093/jnci/djj103
  2. Curtin, J.A., Busam, K., Pinkel, D., Bastian, B., Somatic activation of KIT in distinct subtypes of melanoma (2006) J Clin Oncol., 24, pp. 4340-4346. , https://doi.org/10.1200/JCO.2006.06.2984
  3. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Ewing, R., Mutations of the BRAF gene in human cancer (2002) Nature., 417, pp. 949-954. , https://doi.org/10.1038/nature00766
  4. Chin, L., Garraway, L.A., Fisher, D.E., Malignant melanoma: genetics and therapeutics in the genomic era (2006) Genes Dev., 20, pp. 2149-2182. , https://doi.org/10.1101/gad.1437206
  5. Kanda, J.L., Mucosal melanoma of head and neck: survival analysis and clinicopathological prognostic factors (2003), http://repositorio.unifesp.br/handle/11600/19753, [Article in Portuguese] (Doctoral dissertation) São Paulo
  6. s.n
  7. Rinaldo, A., Shaha, A.R., Patel, S.G., Ferlito, A., Primary mucosal melanoma of the nasal cavity and paranasal sinuses (2001) Acta Otolaryngol., 121, pp. 979-982. , https://doi.org/10.1080/00016480127369
  8. Turri-Zanoni, M., Medicina, D., Lombardi, D., Ungari, M., Balzarini, P., Rossini, C., Pellegrini, W., Kutzner, H., Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases (2013) Head Neck., 35, pp. 1066-1077. , https://doi.org/10.1002/hed.23079
  9. Guo, J., Si, L., Kong, Y., Flaherty, K.T., Xu, X., Zhu, Y., Corless, C.L., Li, S., Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification (2011) J Clin Oncol., 29, pp. 2904-2909. , https://doi.org/10.1200/JCO.2010.33.9275
  10. Chang, A.E., Karnell, L.H., Menck, H.R., The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade (1998) Cancer., 83, pp. 1664-1678. , https://doi.org/10.1002/(SICI)1097-0142(19981015)83:8%3C1664::AID-CNCR23%3E3.0.CO;2-G
  11. Gal, T.J., Silver, N., Huang, B., Demographics and treatment trends in sinonasal mucosal melanoma (2011) Laryngoscope., 121, pp. 2026-2033. , https://doi.org/10.1002/lary.21925
  12. Nandapalan, V., Roland, N.J., Helliwell, T.R., Williams, E.M., Hamilton, J.W., Jones, A.S., Mucosal melanoma of the head and neck (1998) Clin Otolaryngol Allied Sci., 23, pp. 107-116. , https://doi.org/10.1046/j.1365-2273.1998.00099.x
  13. Owens, J.M., Roberts, D.B., Myers, J.N., The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region (2003) Arch Otolaryngol Head Neck Surg., 129, pp. 864-868. , https://doi.org/10.1001/archotol.129.8.864
  14. Haerle, S.K., Soyka, M.B., Fischer, D.R., Murer, K., Strobel, K., Huber, G.F., Holzmann, D., The value of 18F-FDG-PET/ CT imaging for sinonasal malignant melanoma (2012) Eur Arch Otorhinolaryngol., 269, pp. 127-133. , https://doi.org/10.1007/s00405-011-1664-1
  15. Thompson, L.D., Wieneke, J.A., Miettinen, M., Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system (2003) Am J Surg Pathol., 27, pp. 594-611
  16. Moreno, M.A., Hanna, E.Y., Management of mucosal melanomas of the head and neck: did we make any progress? (2010) Curr Opin Otolaryngol Head Neck Surg., 18, pp. 101-106. , https://doi.org/10.1097/MOO.0b013e3283374d31
  17. Penel, N., Mallet, Y., Mirabel, X., Van, J.T., Lefebvre, J.L., Primary mucosal melanoma of head and neck: prognostic value of clear margins (2006) Laryngoscope., 116, pp. 993-995. , https://doi.org/10.1097/01.mlg.0000217236.06585.a9
  18. Moreno, M.A., Roberts, D.B., Kupferman, M.E., DeMonte, F., El-Naggar, A.K., Williams, M., Rosenthal, D.S., Hanna, E.Y., Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M (2010) D. Anderson Cancer Center. Cancer., 116, pp. 2215-2223. , https://doi.org/10.1002/cncr.24976
  19. Willmore-Payne, C., Holden, J.A., Tripp, S., Layfield, L.J., Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis (2005) Hum Pathol., 36, pp. 486-493
  20. Ugurel, S., Hildenbrand, R., Zimpfer, A., La Rosee, P., Paschka, P., Sucker, A., Keikavoussi, P., Schadendorf, D., Lack of clinical efficacy of imatinib in metastatic melanoma (2005) Br J Cancer., 92, pp. 1398-1405. , https://doi.org/10.1038/sj.bjc.6602529
  21. Wyman, K., Atkins, M.B., Prieto, V., Eton, O., McDermott, D.F., Hubbard, F., Byrnes, C., Sosman, J.A., Multicenter phase II trial of high- dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy (2006) Cancer., 106, pp. 2005-2011. , https://doi.org/10.1002/cncr.21834
  22. Becker, J.C., Brocker, E.B., Schadendorf, D., Ugurel, S., Imatinib in melanoma: a selective treatment option based on KIT mutation status? (2007) J Clin Oncol., 25, p. e9. , https://doi.org/10.1200/JCO.2006.08.9664
  23. Antonescu, C.R., Busam, K.J., Francone, T.D., Wong, G.C., Guo, T., Agaram, N.P., Besmer, P., Weiser, M.R., L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition (2007) Int J Cancer., 121, pp. 257-264. , https://doi.org/10.1002/ijc.22681
  24. Rivera, R.S., Nagatsuka, H., Gunduz, M., Cengiz, B., Gunduz, E., Siar, C.H., Tsujigiwa, H., Nagai, N., C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma (2008) Virchows Arch., 452, pp. 27-32. , https://doi.org/10.1007/s00428-007-0524-2
  25. Rivera, R.S., Nagatsuka, H., Siar, C.H., Gunduz, M., Tsujigiwa, H., Han, P.P., Katase, N., Nagai, N., Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma (2008) Oncol Rep., 19, pp. 657-661
  26. Tate, G., Tajiri, T., Suzuki, T., Mitsuya, T., Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary (2009) Cancer Genet Cytogenet., 190, pp. 15-20. , https://doi.org/10.1016/j.cancergencyto.2008.11.002
  27. Daniotti, M., Ferrari, A., Frigerio, S., Casieri, P., Miselli, F., Zucca, E., Collini, P., Parmiani, G., Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT (2009) J Invest Dermatol., 129, pp. 1759-1768. , https://doi.org/10.1038/jid.2008.422
  28. Beadling, C., Jacobson-Dunlop, E., Hodi, F.S., Le, C., Warrick, A., Patterson, J., Town, A., West, R., KIT gene mutations and copy number in melanoma subtypes (2008) Clin Cancer Res., 14, pp. 6821-6828. , https://doi.org/10.1158/1078-0432.CCR-08-0575
  29. Carvajal, R.D., Antonescu, C.R., Wolchok, J.D., Chapman, P.B., Roman, R.A., Teitcher, J., Panageas, K.S., Cane, L., KIT as a therapeutic target in metastatic melanoma (2011) JAMA., 305, pp. 2327-2334. , https://doi.org/10.1001/jama.2011.746
  30. Schoenewolf, N.L., Bull, C., Belloni, B., Holzmann, D., Tonolla, S., Lang, R., Mihic-Probst, D., Dummer, R., Sinonasal, gen ital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations (2012) Eur J Cancer., 48, pp. 1842-1852. , https://doi.org/10.1016/j.ejca.2012.02.049
  31. Zebary, A., Jangard, M., Omholt, K., Ragnarsson-Olding, B., Hansson, J., KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases (2013) Br J Cancer., 109, pp. 559-564. , https://doi.org/10.1038/bjc.2013.373
  32. Lasota, J., Miettinen, M., Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumors (2008) Histopathology., 53, pp. 245-266. , https://doi.org/10.1111/j.1365-2559.2008.02977.x
  33. Hodi, F.S., Corless, C.L., Giobbie-Hurder, A., Fletcher, J.A., Zhu, M., Marino-Enriquez, A., Friedlander, P., Lawrence, D., Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin (2013) J Clin Oncol., 31, pp. 3182-3190. , https://doi.org/10.1200/JCO.2012.47.7836
  34. Lee, S.J., Kim, T.M., Kim, Y.J., Jang, K.T., Lee, H.J., Lee, S.N., Ahn, M.S., Lee, J., Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration: A multicenter trial of Korean Cancer Study Group (UN10-06) (2015) Oncologist., 20, pp. 1312-1319. , https://doi.org/10.1634/theoncologist.2015-0161
  35. Yun, J., Lee, J., Jang, J., Lee, E.J., Jang, K.T., Kim, J.H., Kim, K.M., KIT amplification and gene mutations in acral/mucosal melanoma in Korea (2011) APMIS., 119, pp. 330-335. , https://doi.org/10.1111/j.1600-0463.2011.02737.x
  36. Singer, S., Rubin, B.P., Lux, M.L., Chen, C.J., Demetri, G.D., Fletcher, C.D., Fletcher, J.A., Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors (2002) J Clin Oncol., 20, pp. 3898-3905. , https://doi.org/10.1200/JCO.2002.03.095

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/28
Artigos e Materiais de Revistas Científicas - ODS/03